Skip to content

US · CYPH · BIOTECHNOLOGY

Cypherpunk Technologies Inc. (CYPH) intrinsic value and stock valuation

$1.41as of 2026-11-21 · Mkt cap 41.53M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cypherpunk Technologies Inc. DCF and intrinsic value

InvestorsCraft values CYPH with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CYPH’s statements →

Cypherpunk Technologies Inc. Graham Number

Graham Number: $1.95d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02141 cypherpunk.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
$4.82M
20122025
Free cash flow
-$-43.9M
20122025
Total equity
$153.5M+17.9% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$1.5M
Operating income-$-36.54M-$-70.06M-$-87.04M-$-56.76M-$-41.43M
Net income$4.82M-$-67.56M-$-81.41M-$-54.6M-$-40.59M
EPSd$68.2K-$-1.8M-$-3.98M-$-4.82M-$-4.73M
Operating cash flow-$-43.9M-$-60.3M-$-43.75M-$-49.04M-$-35.16M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-43.9M-$-60.3M-$-43.75M-$-49.04M-$-35.16M
Total assets$163.2M$49.1M$72.8M$58.1M$117.9M
Total debt$40K$270K$260K$520K$470K
Net debt-$-14M-$-46.98M-$-70.38M-$-20.47M-$-114.45M
Total equity$153.5M$35.1M$60.1M$54.6M$107.9M
Cash and short-term investments$14M$47.3M$70.6M$43.8M$114.9M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$1.5M
Cost of revenue$0.00$0.00$430K$0.00$0.00
Gross profit$0.00$0.00-$-430K$0.00$1.5M
Research and development expenses$25.7M$57.2M$73.2M$45M$32.2M
Selling, general and administrative expenses$10.9M$12.9M$13.4M$11.8M$10.8M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$36.5M$70.1M$86.6M$56.8M$42.9M
Cost and expenses$36.5M$70.1M$87M$56.8M$42.9M
Interest income$920K$3.13M$4.03M$930K$10K
Interest expense$20K$0.00$0.00$50K$40K
Depreciation and amortization$0.00$10K$430K$20K$30K
Ebitda-$-36.54M-$-70.05M-$-80.99M-$-54.38M-$-40.54M
Operating income-$-36.54M-$-70.06M-$-87.04M-$-56.76M-$-41.43M
Total other income/expenses, net$46.6M$3.09M$5.63M$2.31M$810K
Income before tax$10.1M-$-66.97M-$-81.41M-$-54.45M-$-40.61M
Income tax expense$5.25M$580K$0.00$150K-$-20K
Net income$4.82M-$-67.56M-$-81.41M-$-54.6M-$-40.59M
Weighted average shares outstanding$66.1M$37.6M$20.5M$11.3M$8.58M
Weighted average diluted shares outstanding$70.7M$37.6M$20.5M$11.3M$8.58M
Balance sheet
20252024202320222021
Cash and short-term investments$14M$47.3M$70.6M$43.8M$114.9M
Net receivables$148M$700K$770K$1.36M$1.19M
Inventory$0.00$0.00$0.00$1.4M$0.00
Total current assets$162.1M$48M$71.6M$53.2M$116.9M
Property, plant and equipment, net$40K$260K$260K$370K$490K
Goodwill and intangible assets$0.00$0.00$0.00$30K$0.00
Long-term investments$150K$0.00$0.00$150K$0.00
Total non-current assets$1.1M$1.08M$1.23M$4.88M$1.04M
Total assets$163.2M$49.1M$72.8M$58.1M$117.9M
Accounts payable$1.98M$4.74M$6.46M$1.54M$4.19M
Short-term debt$40K$270K$260K$270K$430K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.56M$14.1M$12.7M$3.12M$9.99M
Long-term debt$0.00$0.00$0.00$260K$40K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$5.12M$0.00$0.00$330K$40K
Capital lease obligations$40K$270K$260K$520K$470K
Total liabilities$9.68M$14.1M$12.7M$3.45M$10M
Common stock$80K$40K$30K$140K$90K
Retained earnings-$-462.55M-$-467.37M-$-399.58M-$-105.93M-$-263.57M
Accumulated other comprehensive income (loss)-$-100K-$-120K$110K$0.00-$-270K
Total equity$153.5M$35.1M$60.1M$54.6M$107.9M
Total investments$150K$0.00$0.00$22.9M$0.00
Total debt$40K$270K$260K$520K$470K
Net debt-$-14M-$-46.98M-$-70.38M-$-20.47M-$-114.45M
Cash flow statement
20252024202320222021
Net income$4.82M-$-67.56M-$-81.41M-$-54.6M-$-40.59M
Depreciation and amortization$0.00$10K$10K$20K$30K
Stock-based compensation$4.9M$5.5M$5.13M$5.18M$3.48M
Change in working capital-$-8.56M$1.29M$2.51M-$-650K$1.01M
Accounts receivable$150K$0.00$1.3M-$-1.01M-$-1.16M
Inventory$0.00$0.00$0.00$0.00$1.16M
Accounts payable-$-10.42M$900K$710K$0.00$3.9M
Net cash provided by operating activities-$-43.9M-$-60.3M-$-43.75M-$-49.04M-$-35.16M
Investments in property, plant and equipment-$-97M$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$50.4M$0.00$0.00
Net cash used for investing activities-$-97M$0.00$49M$0.00$0.00
Common stock issued$108.1M$40M$0.00$0.00$97.2M
Common stock repurchased$0.00$0.00-$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$107.7M$37.2M-$-30K-$-210K$98M
Net change in cash-$-33.21M-$-23.39M$5.14M-$-49.42M$62.8M
Cash at end of period$14M$47.3M$70.6M$65.5M$114.9M
Operating cash flow-$-43.9M-$-60.3M-$-43.75M-$-49.04M-$-35.16M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-43.9M-$-60.3M-$-43.75M-$-49.04M-$-35.16M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cypherpunk Technologies Inc.

        Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-related protein 1 and is currently progressing through multiple clinical trials for various esophagogastric, gynecologic, and colorectal cancers. Additionally, the company is advancing FL-501, another monoclonal antibody that targets the GDF-15 protein, which is presently in preclinical development. Cypherpunk has established an agreement with Adimab, LLC and BeiGene, Ltd., granting it options and licenses to advance and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Founded in 2011, the company operates from Cambridge, Massachusetts, and was formerly known as Leap Therapeutics, Inc. until its renaming in November 2025.

        CEO
        Douglas E. Onsi
        Employees
        6
        Beta
        0.06

        Explore

        Frequently asked questions

        What is the intrinsic value of Cypherpunk Technologies Inc. (CYPH)?

        InvestorsCraft does not currently publish an intrinsic value for CYPH. How the IC value is calculated.

        Is CYPH undervalued?

        InvestorsCraft does not publish an undervaluation signal for CYPH at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.